Improved progression‐free survival, increased toxicities seen with amivantamab for EGFR‐mutant NSCLC 🔗 Access full article via ACS CancerCancer, Volume 130, Issue 4, Page 496-496, 15 February 2024. Share:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
